MERLIN Biotech seeks to apply proven mRNA technology for the development of novel therapeutics and vaccines to address important unmet medical needs.



MERLIN Biotech is a platform start-up innovative biotechnology spinout from the Baruch S. Blumberg Institute. It is leveraging proven mRNA technology to develop novel therapeutics and vaccines against targets, which address important unmet medical needs that include chronic hepatitis B, adult and pediatric cancers, and Lyme disease.  


MERLIN Biotech’s executive management and boards include a former Moderna Senior VP, a  Nobel Prize winner and global experts in mRNA development, oncology immune-modulators, chronic hepatitis B, and preventive vaccines for Lyme disease.